• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday

    4/29/24 10:47:40 AM ET
    $ALB
    $ALTM
    $CGEM
    $DAVE
    Major Chemicals
    Industrials
    Major Chemicals
    Industrials
    Get the next $ALB alert in real time by email

    U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.

    Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China.

    Tesla shares jumped 10.5% to $185.94 on Monday.

    Here are some other big stocks recording gains in today's session.

    • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares surged 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash.
    • ImmunityBio, Inc. (NASDAQ:IBRX) shares rose 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company announced overall survival results in its QUILT 3.055 study.
    • Koninklijke Philips N.V.  (NYSE:PHG) shares gained 35.5% to $28.56 after the company announced $1.1 billion settlement for Respironics personal injury and medical monitoring litigation. The company also reported better than expected first-quarter earnings and reaffirmed guidance.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares jumped 31.1% to $49.66 after the company announced it received Breakthrough Therapy Designation from the FDA for DCCR extended-release tablets in Prader-Willi Syndrome.
    • Mesoblast Limited (NASDAQ:MESO) gained 20.7% to $7.53.
    • MMTec, Inc. (NASDAQ:MTC) jumped 20% to $3.38.
    • Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) climbed 19% to $1.0250.
    • Phibro Animal Health Corporation (NASDAQ:PAHC) rose 17.7% to $14.98. Zoetis announced plans to sell its medicated feed additive portfolio to Phibro Animal Health for $350 million.
    • Heartland Financial USA, Inc. (NASDAQ:HTLF) rose 17.2% to $41.86 after UMB Financial announced it will acquire the company.
    • Dave Inc. (NASDAQ:DAVE) gained 14.6% to $50.08.
    • Arcadium Lithium plc (NASDAQ:ALTM) rose 14.5% to $4.45.
    • MultiPlan Corporation (NYSE:MPLN) jumped 14% to $0.6566. MultiPlan said it will release its first quarter 2024 financial results on Wednesday, May 8.
    • Exscientia plc (NASDAQ:EXAI) rose 12.7% to $4.5399.
    • Prime Medicine, Inc. (NASDAQ:PRME) gained 11.2% to $4.9182 on FDA clearance of its IND application for PM359.
    • Cullinan Therapeutics, Inc. (NASDAQ:CGEM) climbed 10.7% to $28.02. Cullinan Therapeutics announced appointment of Mary Kay Fenton as Chief Financial Officer.
    • Fulton Financial Corporation (NASDAQ:FULT) gained 9.3% to $17.07. Republic First Bancorp has been seized by U.S. regulators and sold to Fulton Bank, a unit of Fulton Financial Corp.
    • Tellurian Inc. (NYSE:TELL) gained 7.7% to $0.5031.
    • Medifast, Inc. (NYSE:MED) rose 7% to $36.07.
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) rose 6.2% to $1.56.
    • Albemarle Corporation (NYSE:ALB) gained 6% to $123.86, possibly on reports indicating Saudi Arabia is looking to obtain lithium from abroad for its EV efforts.
    • Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose 5.7% to $37.21 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $21 to $45.
    • Paramount Global (NASDAQ:PARA) rose 4.8% to $12.48  on reports of the Redstone family and David Ellison making concessions to investors, with Ellison reportedly proposing to purchase a block of shares at a premium.
    • GrafTech International Ltd. (NASDAQ:EAF) gained 4.4% to $1.65.        
    • Roku, Inc. (NASDAQ:ROKU) rose 4.1% to $58.65. Seaport Global analyst David Joyce upgraded Roku from Neutral to Buy and announced a $74 price target.

    Now Read This: Jim Cramer Likes Palantir, Recommends Pioneer Natural Resources: ‘I Want You To Ka-Ching, Ka-Ching’

    Get the next $ALB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALB
    $ALTM
    $CGEM
    $DAVE

    CompanyDatePrice TargetRatingAnalyst
    Tandem Diabetes Care Inc.
    $TNDM
    3/19/2026$35.00Hold → Buy
    Truist
    Tandem Diabetes Care Inc.
    $TNDM
    3/17/2026$33.00Neutral → Overweight
    Piper Sandler
    Prime Medicine Inc.
    $PRME
    3/12/2026$11.00Outperform
    Oppenheimer
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    Pacific Biosciences of California Inc.
    $PACB
    3/6/2026$1.50Equal Weight → Underweight
    Barclays
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Fulton Financial Corporation
    $FULT
    2/25/2026$24.00Neutral
    DA Davidson
    Tandem Diabetes Care Inc.
    $TNDM
    2/23/2026$50.00Hold → Buy
    Lake Street
    More analyst ratings

    $ALB
    $ALTM
    $CGEM
    $DAVE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair

    March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution that

    3/26/26 9:10:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    GrafTech Announces Graphite Electrode Price Increase

    GrafTech International Ltd. (NYSE:EAF) ("GrafTech," the "Company," "we," or "our") today announced it has informed customers that graphite electrode prices will increase by a minimum of $600 to $1,200 per metric ton, depending on region, effective immediately on uncommitted volume. Over the past three years, market prices for graphite electrodes have declined significantly in each of our key regions and remain below sustainable levels necessary to support continued investment and reliable long-term supply for our customers. In addition, current geopolitical developments are driving increases in our key input costs, including oil‑based raw materials, energy and logistics. GrafTech has ex

    3/26/26 8:00:00 AM ET
    $EAF
    Industrial Machinery/Components
    Energy

    ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

    The QUILT-2.005 randomized clinical trial is on track for final analysis and supplemental Biologics License Application (BLA) submission in 2026 for the BCG-naïve NMIBC carcinoma in situ with or without papillary indication with no additional enrollment required The Independent Data Monitoring Committee (IDMC) confirmed that the fully enrolled study (N=366) is adequately powered to detect the pre-specified difference in complete response rate between the experimental and control arms, and that no additional enrollment is required A planned interim analysis was conducted by the IDMC per the protocol once 50% of enrolled patients (N=183) in Cohort A were evaluable for the primary e

    3/26/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    SEC Filings

    View All

    SEC Form PRE 14A filed by Tandem Diabetes Care Inc.

    PRE 14A - TANDEM DIABETES CARE INC (0001438133) (Filer)

    3/27/26 4:07:59 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Tesla Inc.

    SCHEDULE 13G/A - Tesla, Inc. (0001318605) (Subject)

    3/27/26 1:36:06 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Tandem Diabetes Care Inc.

    SCHEDULE 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    3/27/26 1:18:54 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr Executive Vice President Taylor Bernadette M bought $5,884 worth of $2.50 par value Common Stock (324 units at $18.18) and gifted 425 units of $2.50 par value Common Stock, decreasing direct ownership by 0.16% to 63,472 units (SEC Form 4)

    4 - FULTON FINANCIAL CORP (0000700564) (Issuer)

    12/8/25 4:05:45 PM ET
    $FULT
    Major Banks
    Finance

    Sr Executive Vice President Fiol Andrew B bought $9,178 worth of $2.50 par value Common Stock (505 units at $18.18) and gifted 11,000 units of $2.50 par value Common Stock, decreasing direct ownership by 18% to 42,746 units (SEC Form 4)

    4 - FULTON FINANCIAL CORP (0000700564) (Issuer)

    12/4/25 4:32:41 PM ET
    $FULT
    Major Banks
    Finance

    Large owner Lynx1 Capital Management Lp bought $1,391,686 worth of shares (165,667 units at $8.40) (SEC Form 4)

    4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

    10/30/25 5:13:32 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Johnson Nicholas Mark

    3 - MEDIFAST INC (0000910329) (Issuer)

    3/27/26 5:55:56 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form 4 filed by Mackenzie Jonathan Barrett

    4 - MEDIFAST INC (0000910329) (Issuer)

    3/27/26 5:54:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form 4 filed by Maloney James P.

    4 - MEDIFAST INC (0000910329) (Issuer)

    3/27/26 5:52:54 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tandem Diabetes Care upgraded by Truist with a new price target

    Truist upgraded Tandem Diabetes Care from Hold to Buy and set a new price target of $35.00

    3/19/26 8:24:11 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Tandem Diabetes Care from Neutral to Overweight and set a new price target of $33.00

    3/17/26 7:55:10 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Prime Medicine with a new price target

    Oppenheimer initiated coverage of Prime Medicine with a rating of Outperform and set a new price target of $11.00

    3/12/26 8:54:37 AM ET
    $PRME
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Leadership Updates

    Live Leadership Updates

    View All

    Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment

    March 23, 2026 John DeFord proposed as new member of the Supervisory Board.Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board.Marc Harrison will step down from Philips' Supervisory Board after his second term.Roy Jakobs proposed for re-appointment as President/CEO and Chairman and member of the Board of Management, as previously announced. Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President/CEO. The Supervisory Board wil

    3/23/26 4:30:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Financials

    Live finance-specific insights

    View All

    Philips convenes the Annual General Meeting of Shareholders 2026

    March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board, with effect from May 8, 2026.Proposal to re-appoint Roy Jakobs (Dutch/German, 1974) as President/CEO and Chairman and memb

    3/23/26 5:30:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Fulton Financial Corporation Declares Common and Preferred Dividends

    LANCASTER, Pa., March 17, 2026 /PRNewswire/ -- Fulton Financial Corporation ("Fulton") (NASDAQ:FULT) today announced that its Board of Directors (the "Board") declared a quarterly cash dividend of nineteen cents per share on its common stock, payable on April 15, 2026, to shareholders of record as of April 1, 2026. In addition, Fulton announced that the Board declared a quarterly dividend of $12.81 per share (equivalent to $0.32025 per depositary share) on its Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A, payable on April 15, 2026, to shareholders of record as o

    3/17/26 4:30:00 PM ET
    $FULT
    Major Banks
    Finance

    Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its fin

    3/10/26 7:00:00 AM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALB
    $ALTM
    $CGEM
    $DAVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Albemarle Corporation

    SC 13G/A - ALBEMARLE CORP (0000915913) (Subject)

    12/5/24 7:27:01 PM ET
    $ALB
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials